THE COST EFFECTIVENESS ANALYSIS OF CAPDX VERSUS FOLFOX-4 REGIMENS WITH OR WITHOUT BEVACIZUMAB IN THE FIRST LINE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN HONG KONG

被引：0
|
作者：
Lee, V. W. [1 ]
Cheng, F. [1 ]
Wan, K. P. [2 ]
Chik, J. [2 ]
Chan, D. [3 ]
Cheng, A. [3 ]
Wong, K. H. [2 ]
机构：
[1] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[2] Queen Elizabeth Hosp, Kowloon, Hong Kong, Peoples R China
[3] Princess Margaret Hosp, Kwai Chung, Hong Kong, Peoples R China
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN121
引用
收藏
页码：A109 / A109
页数：1
相关论文
共 50 条
  • [1] A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN
    Darba, J.
    Restovic, G.
    Ramirez de Arellano, A.
    VALUE IN HEALTH, 2008, 11 (06) : A467 - A467
  • [2] Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
    Bai, Liangliang
    Zhang, Pengfei
    Zhou, Kexun
    Liao, Weiting
    Li, Qiu
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 10419 - 10426
  • [3] Cost-analysis of xelox vs. folfox-4 ± bevacizumab (BEV) in metastatic colorectal cancer (MCRC) in an Italian hospital setting
    Garrison, L. P.
    Giuliani, G.
    Ducournau, P.
    Cirrincione, A.
    VALUE IN HEALTH, 2007, 10 (06) : A334 - A334
  • [4] COST-EFFECTIVENESS OF BEVACIZUMAB VERSUS CETUXIMAB VERSUS PANITUMUMAB COMBINED WITH FIRST-LINE FOLFOX FOR METASTATIC COLORECTAL CANCER IN BRAZIL
    Sasse, Andre
    Carvalho, Adriana
    ANNALS OF ONCOLOGY, 2012, 23 : 100 - 100
  • [5] Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study
    Bokemeyer, C.
    Bondarenko, I.
    Makhson, A.
    Hartmann, J. T.
    Aparicio, J.
    Zampino, M.
    Donea, S.
    Ludwig, H.
    Zubel, A.
    Koralewski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
    Grothey, Axel
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (01): : 10 - 11
  • [7] A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
    Axel Grothey
    Nature Clinical Practice Oncology, 2009, 6 : 10 - 11
  • [8] FOLFOX-4 Regimen as a First-line Therapy for Cuban Patients with Metastatic Colorectal Cancer
    Lami, Leonardo
    Areces, Fernando
    Lence, Juan J.
    Arbesu, Maria A.
    MEDICC REVIEW, 2009, 11 (03) : 34 - 38
  • [9] Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher
    Hall, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] PRELIMINARY EFFICACY OF BEVACIZUMAB WITH FIRST LINE CHEMOTHERAPY BY FOLFOX OR FOLFIRI FOR METASTATIC COLORECTAL CANCER (MCRC): AN ALGERIAN EXPERIENCE
    Bensalem, A.
    Bouzid, K.
    ANNALS OF ONCOLOGY, 2009, 20 : 40 - 40
12345